摘要
前言:阿尔茨海默病(AD)在大脑中的病理过程可能比其第一次临床症状和AD症状的出现早20-30年。痴呆症的其他主要原因的症状。因此,提高对本病的早期诊断和鉴别诊断至关重要。事件相关电位(Erp)测量脑电图显示AD的诊断潜力。 目的:比较P 300和N 200电位及反应时间(RT)与脑脊液(CSF)中常用蛋白质生物标志物的效率,包括淀粉样β肽(Aβ1-42),总τ(t-τ),苏氨酸181磷酸化的τ蛋白(p-Tu 181),丝氨酸199磷酸化的τ蛋白(p-Tu 199),苏氨酸231磷酸化的τ蛋白。在轻度认知功能障碍(MCI)和AD患者中鉴别诊断AD的P-Tu 231和VILIP-1。研究对象:49例AD患者,28例MCI患者,4例健康对照者和16例其他主要病因痴呆患者。 结果:ERP(P300RT、N200RT、P 300计数和N 200计数)与蛋白CSF标志物呈中度至强相关性。我们证实了先前的中强相关观测。在ERP与神经心理测试之间,发现AD患者经乙酰胆碱酯酶抑制剂治疗后P 300潜伏期缩短,RT缩短。利用ERP和RT建立d的预测模型在MCI患者中,发现56.3%的MCI患者存在AD的高风险。病理水平为Aβ1-42的MCI患者有PRO。延长P 300潜伏期,提示联合应用ERP和CSF蛋白生物标志物可提高MCI患者对AD的鉴别诊断。此外,研究结果还表明F P 300潜伏期在鉴别AD和FTD患者中的应用。 结论:我们的数据为提高AD的鉴别诊断提供了可能的解决方案,并揭示了csf蛋白标志物t-τ、p-tu 181、p-tu 199、p-tu 231的诊断效率。在临床实践中加入ERP可以改善VILIP-1。
关键词: 阿尔茨海默病,淀粉样β肽,生物标志物,诱发电位,τ蛋白,脑脊液。
Current Alzheimer Research
Title:Event-related Potentials Improve the Efficiency of Cerebrospinal Fluid Biomarkers for Differential Diagnosis of Alzheimer’s Disease
Volume: 15 Issue: 13
关键词: 阿尔茨海默病,淀粉样β肽,生物标志物,诱发电位,τ蛋白,脑脊液。
摘要: Introduction: The pathological process of Alzheimer's disease (AD) in the brain likely begins 20-30 years earlier than the emergence of its first clinical symptoms and symptoms of AD often overlap with the symptoms of other primary causes of dementia. Therefore, it is crucially important to improve early and differential diagnosis of the disease. Event-related potentials (ERP) measured non-invasively by electroencephalography have shown diagnostic potential in AD.
Aims: The aim of this study was to compare the efficiency of P300 and N200 potentials and reaction time (RT) with commonly used protein biomarkers measured in the cerebrospinal fluid (CSF), including amyloid β peptide (β1-42), total tau (t-tau), tau protein phosphorylated at threonine 181 (p-tau181), tau protein phosphorylated at serine 199 (p-tau199), tau protein phosphorylated at threonine 231 (p-tau231), and visinin-like protein 1 (VILIP-1) in differential diagnosis of AD in mild cognitive impairment (MCI) and AD patients.
Subjects: The study involved 49 AD patients, 28 patients with MCI, 4 healthy control subjects and 16 patients with other primary causes of dementia.
Results: ERP (P300RT, N200RT, P300 counting and N200 counting) showed a moderate to strong correlation with protein CSF biomarkers. We confirmed previous observations of moderate to strong correlation between ERP and neuropsychological testing and showed that P300 latency and RT are shortened in AD patients on therapy with acetylcholinesterase inhibitors. Using ERP and RT, a predictive model for determination of AD likelihood in MCI patients was developed, detecting 56.3% of MCI patients with high risk for development of AD in our cohort. MCI patients with pathological levels of Aβ1-42 had prolonged P300 latency, indicating that a combination of ERP and CSF protein biomarkers could improve the differential diagnosis of AD in MCI patients. Additionally, the results suggested the potential of P300 latency in differentiating AD and FTD patients.
Conclusion: Our data provide possible solutions for improvement of differential diagnosis of AD, and reveal that the diagnostic efficiency of CSF protein biomarkers t-tau, p-tau181, p-tau199, p-tau231 and VILIP-1 could be improved by adding ERP in clinical practice.
Export Options
About this article
Cite this article as:
Event-related Potentials Improve the Efficiency of Cerebrospinal Fluid Biomarkers for Differential Diagnosis of Alzheimer’s Disease, Current Alzheimer Research 2018; 15 (13) . https://dx.doi.org/10.2174/1567205015666180911151116
DOI https://dx.doi.org/10.2174/1567205015666180911151116 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Intrahippocampal Amyloid-β (1-40) Injections Injure Medial Septal Neurons in Rats
Current Alzheimer Research The Association Between Diabetes and Cognitive Function in Later Life
Current Aging Science Alzheimer's Disease Prevention and Use of Traditional Plant Medicines
Letters in Drug Design & Discovery Diffuse Correlation Spectroscopy (DCS): A Diagnostic Tool for Assessing Tissue Blood Flow in Vascular-Related Diseases and Therapies
Current Medical Imaging Adalimumab
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Insights from Mouse Models to Understand Neurodegeneration in Down Syndrome
CNS & Neurological Disorders - Drug Targets Gene Therapy as a Novel Pharmaceutical Intervention for Stroke
Current Pharmaceutical Design Chemokines as Potential Therapeutic Targets in Atherosclerosis
Current Drug Targets Difficulties in the Management of Frontal Dementia: Therapeutics Strategies
Letters in Drug Design & Discovery Inappropriate Drug Use in People with Cognitive Impairment and Dementia: A Systematic Review
Current Clinical Pharmacology Risk Factors in Cardiovascular Disease in Systemic Lupus Erythematosus
Current Cardiology Reviews A Partial Failure of Membrane Protein Turnover May Cause Alzheimers Disease: A New Hypothesis
Current Alzheimer Research A Cyclooxygenase-2 Inhibitor Reduces Vascular Wall Thickness and Ameliorates Cognitive Impairment in a Cerebral Small Vessel Diseases Rat Model
Current Alzheimer Research The Impact of Working Memory Training on Cognitive Abilities in Older Adults: The Role of Cognitive Reserve
Current Aging Science Possible Usefulness of Growth Hormone/Insulin-like Growth Factor-I Axis in Alzheimer’s Disease Treatment
Endocrine, Metabolic & Immune Disorders - Drug Targets Actigraphy for Assessing Light Effects on Sleep and Circadian Activity Rhythm in Alzheimer's Dementia: A Narrative Review
Current Alzheimer Research Tianeptine: A Novel Atypical Antidepressant that May Provide New Insights into the Biomolecular Basis of Depression
Recent Patents on CNS Drug Discovery (Discontinued) New Promises to Cure Cancer and Other Genetic Diseases/Disorders: Epi-drugs Through Epigenetics
Current Topics in Medicinal Chemistry EDITORIAL: Neuroprotection Mechanisms and their Potential Applications
Current Neuropharmacology Ongoing In Vivo Studies with Cytoskeletal Drugs in Tau Transgenic Mice
Current Alzheimer Research